FULCRUM PHARMACEUTICALS

Fulcrum Pharmaceuticals applies computational chemistry, structural biology and thermodynamics to achieve accelerated design and development of drug products. Founded in 2002, Fulcrum has developed a portfolio of proprietary lead compounds targeted at inflammatory disease, osteoporosis, infectious disease and oncology. This portfolio includes small molecule inhibitors of receptors and enzymes, small molecule mimics of antibodies and receptors, and "adaptive" anti-infectives (drugs capable of overcoming resistance). Fulcrum's strategy is to out-license a portion of its pipeline, while retaining selected compounds for internal development. For more information, visit www.fulcrumpharmaceuticals.com.